A randomised, controlled, double-blind, parallel group, multi-country study to investigate the safety and tolerance of a partly fermented infant formula containing prebiotic oligosaccharides in healthy term infants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
252
Infants are randomized to one of two infant formulas from \<14 days of age to 17 weeks of age.
Poliklinika Ginekologiczno-Położnicza Sp. z o.o. Sp. k.
Bialystok, Poland
RECRUITINGWeight gain (infant formula comparison)
Equivalence of weight gain per day (g/d) from baseline until 17 weeks of age in subjects receiving the test product compared to infants receiving the control product
Time frame: 17 weeks
Weight gain (human milk comparison)
Equivalence of weight gain per day (g/d) from baseline until 17 weeks of age in subjects receiving the test product compared to infants receiving human milk
Time frame: 17 weeks
Recumbent Length gain
Equivalence of length gain per day (mm/d) from baseline until 17 weeks of age in subjects receiving the test product compared to infants receiving the control product or human milk
Time frame: 17 weeks
Head circumference gain
Equivalence of head circumference gain per day (mm/d) from baseline until 17 weeks of age in subjects receiving the test product compared to infants receiving the control product or human milk
Time frame: 17 weeks
Parent-reported GI Tolerance Parameters (daily diary)
Information on regurgitation and vomiting will be collected by a daily diary that is completed by the parents.
Time frame: 17 weeks
Parent-Reported Stool Characteristics (adapted Amsterdam Stool Scale)
Information on stool consistency (4-point scale) and stool frequency (number of stools per day) will be collected by a daily diary that is completed by the parents. Occurrence of diarrhea like-symptoms and constipation-like symptoms will be derived from the stool frequency and consistency data.
Time frame: 17 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Incidence of treatment-related adverse events
Number of adverse events (by "System/Organ Class" and "Preferred term" according the MedDRA) as assessed and reported by the investigator.
Time frame: 17 weeks
Severity of treatment-related adverse events
Severity of adverse events (by "System/Organ Class" and "Preferred term" according the MedDRA) as assessed and reported by the investigator.
Time frame: 17 weeks